Westhampton Capital’s Gilead Sciences GILD Stock Holding History

Westhampton Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,350	Closed	-$207K	–	111
2022 Q2	$207K	Sell	3,350 -700	-17%	-$43.3K	0.15%	110
2022 Q1	$241K	Sell	4,050 -60	-1%	-$3.83K	0.16%	108
2021 Q4	$298K	Sell	4,110 -200	-5%	-$13.8K	0.18%	98
2021 Q3	$301K	Sell	4,310 -100	-2%	-$7.03K	0.21%	98
2021 Q2	$304K	Buy	4,410 +150	+4%	+$10K	0.2%	101
2021 Q1	$275K	Sell	4,260 -200	-4%	-$12.9K	0.19%	101
2020 Q4	$260K	Sell	4,460 -4,025	-47%	-$243K	0.19%	95
2020 Q3	$536K	Sell	8,485 -125	-1%	-$8.67K	0.44%	63
2020 Q2	$662K	Buy	8,610 +200	+2%	+$15.3K	0.58%	52
2020 Q1	$629K	Sell	8,410 -700	-8%	-$48.4K	0.65%	47
2019 Q4	$592K	Hold	9,110	–	–	0.48%	60
2019 Q3	$577K	Hold	9,110	–	–	0.48%	55
2019 Q2	$615K	Buy	+9,110	New	+$599K	0.52%	54

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Westhampton Capital's GILD Position: Q3 2022 in Review

Westhampton Capital sold out of Gilead Sciences (GILD) in Q3 2022, closing a stake of 3,350 shares — an estimated $207K sold.

Westhampton Capital first reported a position in GILD in Q2 2019 and held it in 13 quarters. The position peaked at $662K in Q2 2020. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

Westhampton Capital reported no remaining Gilead Sciences position as of Q3 2022 after selling out during the quarter.
Westhampton Capital sold 3,350 Gilead Sciences shares in Q3 2022, an estimated $207K.
Westhampton Capital first reported a position in Gilead Sciences in Q2 2019 and held it in 13 quarters.
Westhampton Capital's Gilead Sciences position peaked at $662K in Q2 2020.
1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Westhampton Capital's 13F filing for Q3 2022, filed 26 Oct 2022.